We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Clinigen Group Plc | LSE:CLIN | London | Ordinary Share | GB00B89J2419 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 925.00 | 924.50 | 925.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCLIN
Clinigen Group plc
08 October 2021
8th October 2021
Clinigen signs agreement with Humanigen for
Lenzilumab Managed Access Program
Clinigen Group plc (AIM: CLIN, 'Clinigen'), the global pharmaceutical Services and Products company, announces it has signed an exclusive agreement with Humanigen, Inc. ('Humanigen') to implement a Managed Access Program for lenzilumab.
Once set up the program will enable access to lenzilumab on a case-by-case basis for hospitalized patients with COVID-19 where the treating physician deems there to be no suitable alternatives and where regulations allow. The program will be available in the following 16 European countries: Austria, Bulgaria, Croatia, Cyprus, Denmark, Estonia, France, Greece, Ireland, Lithuania, Luxembourg, Netherlands, Portugal, Spain, Sweden, and Switzerland. Lenzilumab is an investigational product and is not currently authorized or approved in any country.
Under the terms of the agreement, Clinigen will manage key elements of the program including regulatory oversight, logistics and access management.
Pete Belden, Executive Vice President Services Division, Clinigen, said:
"We are pleased to partner with Humanigen to offer this important treatment option to help address a significant unmet need for hospitalized patients across Europe. This agreement underlines Clinigen's strength in partnering with biotechnology companies to provide services that enable quicker and broader access to critical medicines ."
Timothy E. Morris Chief Operating Officer and Chief Financial Officer, Humanigen, said:
"While we complete a Marketing Authorization Application for lenzilumab and await the associated review by the European Medicines Agency, as well as a decision regarding conditional marketing authorization, the Managed Access Program will enable Humanigen to respond positively to requests for access from healthcare professionals to treat hospitalized patients where allowed by the local competent authorities. We look forward to working with Clinigen."
Patients seeking information should contact their physician.
- Ends -
Contact details
Clinigen Group plc +44 (0) 1283 495010 Pete Belden, EVP Services Division investors@clinigengroup.com Rob Fox, VP Investor Relations and Corporate Development Consilium Strategic Communications Mary-Jane Elliott / Matthew Cole / Jessica Tel: +44 (0) 20 3709 5700 Hodgson Clinigen@consilium-comms.com Humanigen Ken Trbovich, SVP Investor Relations Tel: +1 (650) 410-3206 trbo@ humanigen.com
Notes to Editors
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global, specialist pharmaceutical services and products company focused on providing ethical access to medicines. Its' mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa and the Asia Pacific.
Clinigen has more than 1,000 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies; interacting with over 20,000 healthcare professionals across more than 120 countries.
For more information on Clinigen, please visit http://www.clinigen.com
About Humanigen
Humanigen is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called 'cytokine storm'. Humanigen has submitted lenzilumab to Medicines and Health Regulatory Agency in the United Kingdom for a rolling review towards potential Marketing Authorization. Humanigen is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 and CD19-targeted CAR-T cell therapies and is also exploring the effectiveness of lenzilumab in other inflammatory conditions such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation, eosinophilic asthma, and rheumatoid arthritis. For more information, visit www.humanigen.com and follow Humanigen on LinkedIn, Twitter, and Facebook.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAUPGUCUUPGPUM
(END) Dow Jones Newswires
October 08, 2021 02:00 ET (06:00 GMT)
1 Year Clinigen Chart |
1 Month Clinigen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions